Long-term safety of facilitated subcutaneous immunoglobulin treatment in pregnant women with primary immunodeficiency diseases: results from a registry study.
Sign Up to like & getrecommendations! Published in 2022 at "Immunotherapy"
DOI: 10.2217/imt-2021-0336
Abstract: Aim: Clinical outcomes of women who become pregnant during/after facilitated subcutaneous immunoglobulin (fSCIG) treatment are not well characterized. Materials & methods: This noninterventional, prospective, open-label, post authorization, pregnancy registry study assessed safety outcomes in mothers with… read more here.
Keywords: safety; facilitated subcutaneous; registry study; treatment ... See more keywords